Houston, TX, (April 20, 2005) Cytogenix, Inc. (CYGX: OTC: BB)
CytoGenix, Inc. (CYGX: OTC: BB) has engaged the global engineering firm of Alfa Laval Biokinetics, Inc. headquartered in Philadelphia, PA to conduct the conceptual engineering phase of the company's DNA plant construction project. This production plant will house the Company's revolutionary cell-free process that produces high purity DNA at much lower costs than traditional recombinant bacteria fermentation methods. Work will commence this week with a site survey by Alfa Laval engineers to the proposed Houston location.
Frank Vazquez, CytoGenix' Executive Vice President and COO commented, "We decided to get into the DNA production business because the extremely high price of pharmaceutical quality DNA would make several of our drugs economically unfeasible. We know that other companies are in a similar situation, thus creating a significant latent demand for low cost pharmaceutical grade DNA. In the next few years, this technology will drive the overall DNA therapeutic market especially for cost-sensitive products such DNA vaccines and antimicrobials.
This is the first step of a multi-phase project that will include architectural design, engineering, permitting, construction, equipment specification, installation, validation and certification. Constructing a state-of-art FDA compliant biopharmaceutical facility to achieve maximum benefit from this new technology requires a highly experienced and creative team of scientists and engineers."
"Alfa Laval is a leading firm in biopharmaceutical plant design and construction with a wide breadth of experience on projects for major pharmaceutical and biotechnology companies worldwide. Their engineers are recognized in the industry for their technical expertise. As a smaller company, we will greatly benefit from this wealth of experience and resources." added Mr. Vazquez.
Robert A. Bader, Sr. Vice President of Technology for Alfa Laval Biokinetics commented, "The thing that impressed me most about CytoGenix is the simplicity of their process. They have developed a method of producing DNA that avoids the complication of conventional microbial fermentation and the complex purification processes associated with that technology. The purpose of the Conceptual Study is to demonstrate the significant cost savings associated with the CytoGenix technology."
CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and over 44 international or US pending patent applications claiming methods and materials in connection with this platform technology.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.
Contact: CytoGenix, Inc., Communications Director - Juan Ferreira, (407) 774-9949
